Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

CSCC Treatment Options: Cemiplimab and Pembrolizumab

April 19th 2023

Nikhil Khushalani, MD, gives a comprehensive overview of cemiplimab and pembrolizumab for treating CSCC.

Choosing Systemic Therapies for Patients with Unresectable or Metastatic CSCC

April 19th 2023

Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.

Pembrolizumab Yields High Response Rates for Patients With Unresectable Metastatic Desmoplastic Melanoma

April 17th 2023

Patients with unresectable metastatic desmoplastic melanoma achieved high response rates when treated with single-agent pembrolizumab in the SWOG S1512 trial, according to data presented during the 2023 AACR Annual Meeting.

Adjuvant mRNA-4157 Plus Pembrolizumab Improves RFS in Resected High-Risk Melanoma

April 16th 2023

mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

Dr Verschraegen on Toxicities Associated with Single-agent vs Doublet Immunotherapy in Melanoma

April 14th 2023

Claire F. Verschraegen, MD, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma.

Multidisciplinary Management of CSCC

April 12th 2023

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.

Unmet Needs and Prognosis for CSCC and Melanoma

April 12th 2023

Skin cancer experts discuss prognosis and unmet needs in the cutaneous squamous cell carcinoma and melanoma treatment spaces.

Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates

April 12th 2023

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials

April 12th 2023

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

EMA Awards PRIME Scheme Designation to mRNA-4157/V940 Plus Pembrolizumab in High-risk Melanoma

April 7th 2023

The European Medicines Agency has granted Priority Medicines scheme designation to the personalized cancer vaccine mRNA-4157/V940 and pembrolizumab for use as adjuvant treatment in patients with high-risk, stage III or IV melanoma following complete resection.

Pembrolizumab/Lenvatinib Combo Misses OS End Points in Select Advanced Melanoma and mCRC

April 7th 2023

The phase 3 LEAP-003 and LEAP-017 trials evaluating pembrolizumab plus lenvatinib did not meet their primary end points of overall survival in select patients with unresectable or metastatic melanoma and metastatic colorectal cancer, respectively.

Clinical Experience With Neoadjuvant IO Therapy in Melanoma

April 5th 2023

Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.

Evolving Treatment Paradigm of Resectable CSCC

April 5th 2023

Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.

TAVO-EP Plus Pembrolizumab Fails to Meet ORR End Point in Anti–PD-1–Refractory Advanced Melanoma

April 4th 2023

The combination of the interleukin-12 encoding plasmid TAVO™-EP plus pembrolizumab did not meet the prespecified primary end point for overall response rate in patients with advanced melanoma that was refractory to anti–PD-1 therapy.

Dr Pavlick on the Mechanisms of Action of RP1 in Cutaneous Melanoma

April 3rd 2023

Anna C. Pavlick, DO, discusses the mechanism of action of vusolimogene oderparepvec in patients with anti–PD-1–failed cutaneous melanoma.

Overview of Cutaneous Squamous Cell Carcinoma and Melanoma

March 31st 2023

A panel of skin cancer experts give an overview of cutaneous squamous cell carcinoma and melanoma.

Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma

March 29th 2023

Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.

Staging and Risk Stratification’s Impact on Treatment Approach in CSCC

March 29th 2023

Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.

FDA Approval Sought for Lifileucel in Unresectable or Metastatic Melanoma

March 27th 2023

Iovance Biotherapeutics has submitted a rolling biologics license application to the FDA seeking the approval of the tumor infiltrating lymphocyte therapy lifileucel for the treatment of patients with advanced unresectable or metastatic melanoma who progressed on or after prior anti–PD-1/L1 therapy and targeted therapy.

Isolated Hepatic Perfusion With Melphalan Improves PFS, ORR for Patients With Isolated Uveal Melanoma Liver Metastases

March 24th 2023

A one-time treatment with isolated hepatic perfusion with melphalan improved median progression-free survival compared with best alternative treatment for patients with previously untreated isolated liver metastases from uveal melanoma.